Search clinical trials for: 150 mg LX3305 QD

Total 2229 results

Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Warner Chilcott

Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Postmenopausal Osteoporosis

United States
Georgetown University

Unknown

Nilotinib in Huntington's Disease (Tasigna HD)

Huntington Disease

United States
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
Novartis Pharmaceuticals

Terminated

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma

Germany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
Ariad Pharmaceuticals

Terminated

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (OPTIC-2L)

Chronic Phase Chronic Myeloid Leukemia

Belgium
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland, Germany
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects (INX-189-004)

Healthy

United States
vTv Therapeutics

Not yet recruiting

Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1)

Diabetes Mellitus, Type 1
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
ImmunityBio, Inc.

Completed

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Kaposi's Sarcoma | AIDS | HIV Positive

United States
AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
University of Turin, Italy

Withdrawn

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

HIV Infection

Italy
Columbia University

Withdrawn

Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

Chronic Fatigue Syndrome

United States
Rigel Pharmaceuticals

Withdrawn

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

IGA Nephropathy
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Cephalon

Completed

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

Chronic Shift Work Sleep Disorder

United States
Taiwan Liposome Company

Completed

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Osteoarthritis of the Knee

Taiwan, Australia
Janssen Research & Development, LLC

Completed

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
GlaxoSmithKline

Completed

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Multiple Sclerosis

Italy, Germany, Spain, United Kingdom, Australia, Netherlands, New Zealand, Russian Federation, France, Canada, Austria, Poland, Finland, Norway
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
XenoPort, Inc.

Completed

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Gastroesophageal Reflux

United States
Eisai Inc.

Active, not recruiting

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Breast Neoplasms | Receptors, Estrogen | Genes, Erbb-2

United States, United Kingdom
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Migraine
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
Corcept Therapeutics

Completed

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Healthy

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Advanced Basal Cell Carcinoma

United States
Amicus Therapeutics

Recruiting

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Fabry Disease

Spain, United States, Japan, Australia, France, Portugal
Dr. Reddy's Laboratories Limited

Completed

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Psoriasis

United States
CollaGenex Pharmaceuticals

Completed

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

Rosacea

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Locally Advanced Rectal Cancer

United States, Spain
Shanghai Antengene Corporation Limited

Terminated

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

Advanced Solid Tumors

China
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Fondazione Oncotech

Not yet recruiting

NEOadjuvant Abemaciclib and GIredestrant triaL in Patients With ER-positive, HER2-negative Early Breast Cancer (Neo-AGILE)

Breast Cancer

Italy
EMD Serono

Terminated

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

Fatigue

United States

Search clinical trials for: 150 mg LX3305 QD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations